WARF: P05278US

  • Assigned to WARF as biological material.

Cell Line for Evaluating Influenza Virus Sensitivity to NA Inhibitors


Yoshihiro Kawaoka

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a cell line that is capable of universally monitoring the sensitivity of human influenza virus isolates to NA inhibitors.
OVERVIEWThe extensive use of neuraminidase (NA) inhibitors to treat influenza virus infections by reducing viral sialidase activity requires close monitoring for resistant variants. However, cultured cells do not provide a reliable means of evaluating the susceptibility of human influenza virus isolates to NA inhibitors. The growth of influenza viruses in most cell lines is not inhibited by these drugs, even though their sialidase activity may be drug-sensitive.
THE INVENTIONA UW-Madison researcher has developed a cell line that is capable of universally monitoring the sensitivity of human influenza virus isolates to NA inhibitors. This Madin-Darby canine kidney (MDCK) cell line has been modified so it overexpresses the human β-galactosidase α2,6-sialyltransferase I (ST6Gal I) gene.

Several influenza virus isolates were tested in this cell line. The sensitivity of the viruses to an NA inhibitor correlated with the sensitivity of viral sialidase to the compound, demonstrating the potential utility of this cell line for detecting viruses that are resistant to NA inhibitors.
  • Development of vaccines and NA inhibitors
  • Can be used universally to monitor the sensitivity of clinical human influenza virus isolates to NA inhibitors
  • Enables the detection of NA-inhibitor resistant variants
  • Supports efficient growth of human influenza virus—allows viruses to be grown to up to 20-fold higher concentration than is possible in standard MDCK cells
  • May be used to isolate influenza viruses from clinical samples
For More Information About the Inventors
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.